Matching articles for "sacubitril"

Apoaequorin (Prevagen) to Improve Memory

   
The Medical Letter on Drugs and Therapeutics • November 1, 2021;  (Issue 1636)
A synthetic form of the protein apoaequorin is the active ingredient in the over-the-counter dietary supplement Prevagen (Quincy Bioscience), which is heavily marketed to improve...
A synthetic form of the protein apoaequorin is the active ingredient in the over-the-counter dietary supplement Prevagen (Quincy Bioscience), which is heavily marketed to improve memory.
Med Lett Drugs Ther. 2021 Nov 1;63(1636):175-6 | Show Full IntroductionHide Full Introduction

Drugs for Chronic Heart Failure

   
The Medical Letter on Drugs and Therapeutics • June 14, 2021;  (Issue 1626)
Among patients with chronic heart failure, those with a left ventricular ejection fraction (LVEF) ≤40% are considered to have heart failure with reduced ejection fraction (HFrEF). Patients with a LVEF...
Among patients with chronic heart failure, those with a left ventricular ejection fraction (LVEF) ≤40% are considered to have heart failure with reduced ejection fraction (HFrEF). Patients with a LVEF ≥50% are considered to have heart failure with preserved ejection fraction (HFpEF). Those with a LVEF of 41-49% are an intermediate group more similar to patients with HFpEF.
Med Lett Drugs Ther. 2021 Jun 14;63(1626):89-96 | Show Full IntroductionHide Full Introduction

In Brief: Sacubitril/Valsartan (Entresto) Expanded Indication

   
The Medical Letter on Drugs and Therapeutics • May 3, 2021;  (Issue 1623)
The oral fixed-dose combination of the neprilysin inhibitor sacubitril and the angiotensin receptor blocker (ARB) valsartan (Entresto – Novartis) was approved in 2015 to reduce the risk of...
The oral fixed-dose combination of the neprilysin inhibitor sacubitril and the angiotensin receptor blocker (ARB) valsartan (Entresto – Novartis) was approved in 2015 to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction (HFrEF; LVEF <40%). The FDA has now expanded its indication to include patients with chronic heart failure with any LVEF; the label specifies that benefits are most clearly evident in patients with LVEF below normal. Entresto is the first drug to be approved in the US for this indication.
Med Lett Drugs Ther. 2021 May 3;63(1623):65 | Show Full IntroductionHide Full Introduction

Vericiguat (Verquvo) for Heart Failure

   
The Medical Letter on Drugs and Therapeutics • March 8, 2021;  (Issue 1619)
The FDA has approved vericiguat (Verquvo – Merck), an oral soluble guanylate cyclase (sGC) stimulator, to reduce the risk of hospitalization for heart failure and cardiovascular (CV) death following a...
The FDA has approved vericiguat (Verquvo – Merck), an oral soluble guanylate cyclase (sGC) stimulator, to reduce the risk of hospitalization for heart failure and cardiovascular (CV) death following a worsening heart failure event (hospitalization for heart failure or treatment with IV diuretics as an outpatient) in patients with symptomatic chronic heart failure and left ventricular ejection fraction (LVEF) <45%. Vericiguat is the second sGC stimulator to be marketed in the US. Riociguat (Adempas), which is FDA-approved for treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension, was the first.
Med Lett Drugs Ther. 2021 Mar 8;63(1619):36-7 | Show Full IntroductionHide Full Introduction

Comparison Table: Some Drugs for HFrEF (online only)

   
The Medical Letter on Drugs and Therapeutics • March 8, 2021;  (Issue 1619)
...
View the Comparison Table: Some Drugs for HFrEF
Med Lett Drugs Ther. 2021 Mar 8;63(1619):e1-14 | Show Full IntroductionHide Full Introduction

Empagliflozin (Jardiance) for Heart Failure

   
The Medical Letter on Drugs and Therapeutics • November 16, 2020;  (Issue 1611)
In a randomized, placebo-controlled trial, the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (Jardiance – Boehringer Ingelheim/Lilly) reduced the composite risk of cardiovascular death or...
In a randomized, placebo-controlled trial, the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (Jardiance – Boehringer Ingelheim/Lilly) reduced the composite risk of cardiovascular death or hospitalization for worsening heart failure (HF) in patients with heart failure with reduced ejection fraction (HFrEF), whether or not they had type 2 diabetes. To date, empagliflozin has not been approved by the FDA for such use. The SGLT2 inhibitor dapagliflozin (Farxiga) was approved by the FDA for this indication earlier this year.
Med Lett Drugs Ther. 2020 Nov 16;62(1611):177-8 | Show Full IntroductionHide Full Introduction

Correction: Drugs for Chronic Heart Failure

   
The Medical Letter on Drugs and Therapeutics • July 1, 2019;  (Issue 1575)
In our Drugs for Chronic Heart Failure article,1 our description of the PARADIGM-HF trial comparing the combination of the ARB valsartan and the neprilysin inhibitor sacubitril (Entresto) with the ACE inhibitor...
In our Drugs for Chronic Heart Failure article,1 our description of the PARADIGM-HF trial comparing the combination of the ARB valsartan and the neprilysin inhibitor sacubitril (Entresto) with the ACE inhibitor enalapril for treatment of heart failure with reduced ejection fraction (HFrEF) characterized the dosage of enalapril as "suboptimal". Some readers have objected to that characterization.

The FDA-approved dosage of enalapril for treatment of HFrEF is 2.5-20 mg twice daily. In PARADIGM-HF, the dosage was capped at 10 mg twice daily, a widely used dosage that has been shown to reduce mortality in patients with HFrEF.2 In the trial, the rate of death from cardiovascular causes or hospitalization for heart failure was significantly lower with the combination of valsartan and sacubitril than with enalapril 10 mg twice daily (21.8% vs 26.5%). Whether allowing titration to 20 mg twice daily would have changed that result is a reasonable question, but there is no direct evidence that the higher dosage is more effective for this indication.3 We have removed the word "suboptimal" from the article as it appears online.

  1. Med Lett Drugs Ther 2019; 61:49.
  2. JJ McMurray et al. N Engl J Med 2014; 371:993.
  3. N Bartell and WH Frishman. Cardiol Rev 2017; 25:315.


Download complete U.S. English article

Med Lett Drugs Ther. 2019 Jul 1;61(1575):104 | Show Full IntroductionHide Full Introduction

Drugs for Chronic Heart Failure

   
The Medical Letter on Drugs and Therapeutics • April 8, 2019;  (Issue 1569)
Patients with a left ventricular ejection fraction (LVEF) ≤40% are considered to have heart failure with reduced ejection fraction (HFrEF). Patients with a LVEF ≤50% and symptoms of heart failure are...
Patients with a left ventricular ejection fraction (LVEF) ≤40% are considered to have heart failure with reduced ejection fraction (HFrEF). Patients with a LVEF ≤50% and symptoms of heart failure are considered to have heart failure with preserved ejection fraction (HFpEF). There is little evidence that drug treatment improves clinical outcomes in patients with HFpEF.
Med Lett Drugs Ther. 2019 Apr 8;61(1569):49-54 | Show Full IntroductionHide Full Introduction

Expanded Table: Some Drugs for HFrEF (online only)

   
The Medical Letter on Drugs and Therapeutics • April 8, 2019;  (Issue 1569)
...
View the Expanded Table: Some Drugs for HFrEF
Med Lett Drugs Ther. 2019 Apr 8;61(1569):e57-62 | Show Full IntroductionHide Full Introduction

Sacubitril/Valsartan (Entresto) for Heart Failure

   
The Medical Letter on Drugs and Therapeutics • August 3, 2015;  (Issue 1474)
The FDA has approved Entresto (Novartis), an oral fixed-dose combination of the neprilysin inhibitor sacubitril and the angiotensin receptor blocker (ARB) valsartan, to reduce the risk of cardiovascular...
The FDA has approved Entresto (Novartis), an oral fixed-dose combination of the neprilysin inhibitor sacubitril and the angiotensin receptor blocker (ARB) valsartan, to reduce the risk of cardiovascular death and heart failure hospitalization in patients with heart failure with reduced ejection fraction. Sacubitril is the first neprilysin inhibitor to become available in the US.
Med Lett Drugs Ther. 2015 Aug 3;57(1474):107-9 | Show Full IntroductionHide Full Introduction

Drugs for Chronic Heart Failure

   
The Medical Letter on Drugs and Therapeutics • January 19, 2015;  (Issue 1460)
Heart failure is usually associated with left ventricular dysfunction. According to recent guidelines, patients with a left ventricular ejection fraction (LVEF) ≤40% are considered to have heart failure...
Heart failure is usually associated with left ventricular dysfunction. According to recent guidelines, patients with a left ventricular ejection fraction (LVEF) ≤40% are considered to have heart failure with reduced ejection fraction (HFrEF) or systolic heart failure. Patients with a LVEF ≥50% and symptoms of heart failure are considered to have heart failure with preserved ejection fraction (HFpEF) or diastolic heart failure; there is little evidence that drug treatment improves clinical outcomes in these patients. The treatment of acute heart failure is not included here.
Med Lett Drugs Ther. 2015 Jan 19;57(1460):9-13 | Show Full IntroductionHide Full Introduction